Revolution Medicines just delivered a week where the stock and the Street moved in the same direction at the same time — a relatively rare alignment that has the options market taking notice in its own telling way.
The clearest post-earnings signal came not from short sellers but from analysts. Five firms raised price targets on August 6, the day after results, all maintaining positive ratings. RBC Capital lifted to $203 from $182. Evercore ISI moved to $230 from $220. Guggenheim went to $240 from $235. Needham matched that at $240. The consensus mean now runs at $213.66, still modestly above the current price of $205.15, suggesting the Street sees room but isn't dramatically stretching. What's notable is the uniformity — no firm moved to the sidelines, and the direction of travel over the past four weeks has been exclusively upward revisions across every firm that touched the name.
Options positioning tells a more striking story. Call demand has surged to the point where the put/call ratio collapsed to 0.55 on August 7 — more than two standard deviations below its 20-day average of 0.70 and the most bullish reading in recent months. For context, the PCR had been drifting in a tight band between 0.73 and 0.75 through most of July before Thursday's sharp drop. That flip points to heavy fresh call buying, likely tied to momentum chasers positioning after the post-earnings pop. The stock gained 9.4% on the week to close at $205.15, adding to a 7.7% monthly gain.
Short interest sits at 7.2% of the free float — meaningful for a biotech, and up roughly 5.7% over the past month as the stock climbed. Shorting into strength has been a recurring theme here. Despite that build, borrow conditions offer no friction to new short sellers. Availability is extraordinarily loose at 1,682%, meaning there are roughly sixteen available shares for every one currently on loan. Cost to borrow has dropped 15% on the week to just 0.40%, near the low end of its 30-day range. The lending market is not exerting any pressure on the short base, and the ORTEX short score of 47.9 — roughly mid-range — reflects that balance. Positioning looks more cautious on the long side through options than it does crowded on the short side.
The bull case rests on RVMD's RAS(ON) inhibitor pipeline and the company's history of beating estimates — its EPS surprise factor ranks in the 80th percentile. The Q2 print that triggered Thursday's analyst chorus delivered a 2.2% next-day gain, modest relative to the size of the analyst reaction. Bears point to pre-profitability fundamentals: price-to-book is running at 27.7x, the EV/EBITDA multiple is deeply negative, and the company has no near-term revenue base to anchor valuation. That tension between long-duration optionality and no current earnings is the defining debate. Adage Capital added over 3.2 million shares as of Q1, one of the larger institutional commitments in the top-15 holder list, while Baker Bros. and Janus Henderson each hold positions above 4.5% — specialist healthcare money that tends to be conviction-driven rather than momentum-chasing.
The next scheduled earnings event is November 6. Between now and then, the watch item is whether clinical trial updates or FDA interaction timelines for the lead RAS program provide fresh catalysts — and whether the options market's current call-heavy tilt moderates as the post-earnings momentum fades.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
